Systemic Delivery of ApoB <sup>11</sup> ‐Conjugated Antisense Oligonucleotide Reduces α‐Synuclein Aggregates and Improves Cognitive and Motor Function in a DLB Mouse Model
Collectively, our findings suggest that the reduction of α-syn through the use of systemically-delivered ApoB<sup>11</sup>:ASO α-syn is a safe disease-modifying treatment for DLB and may hold promise as a future therapeutic for other synucleinopathies.
Authors
- Robert A. Rissman (ORCID: https://orcid.org/0000-0001-9245-8278)
- Rijwan Uddin Ahammad
- Brian Spencer (ORCID: https://orcid.org/0000-0002-7486-1941)
Institutions
- University of Southern California (US)
- Autism Research Institute (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103970
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00